Janus kinase (JAK) inhibitors are a type of medication called a disease-modifying antirheumatic drug (DMARD).1 DMARDs reduce the symptoms of autoimmune diseases, in which an overactive immune system attacks the body’s healthy cells.3
JAK inhibitors halt the processes that tell the body to create too many cytokine proteins, which cause inflammation. They do this by blocking the messaging pathways that erroneously tell the body to overproduce cytokines.1
When these pathways are blocked, inflammation decreases, and symptoms of conditions like eczema, rheumatoid arthritis, and ulcerative colitis are alleviated.